A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

NCT04948554 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
5
Enrollment
INDUSTRY
Sponsor class

Stopped Business Reasons

Conditions

Interventions

Sponsor

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA